<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVESPharmacological agents for diabetic <z:hpo ids='HP_0009830'>peripheral neuropathy</z:hpo> (DN) target a number of mechanisms, including <z:chebi fb="199" ids="26708">sodium</z:chebi>-channel function and γ-aminobutyric acid-minergic processes </plain></SENT>
<SENT sid="1" pm="."><plain>At present, prescription is undertaken on a trial-and-error basis, leading to prolonged medication trials and greater healthcare costs </plain></SENT>
<SENT sid="2" pm="."><plain>Nerve-excitability techniques are a novel method of assessing axonal ion-channel function in the clinical setting </plain></SENT>
<SENT sid="3" pm="."><plain>The aim of this study was to determine the effects of axonal ion-channel dysfunction on <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e>-specific quality-of-life (QoL) measures in DN.RESEARCH DESIGN AND METHODSFifty-four patients with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> underwent comprehensive neurologic assessment, nerve-conduction studies, and nerve-excitability assessment </plain></SENT>
<SENT sid="4" pm="."><plain><z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">Neuropathy</z:e> severity was assessed using the Total <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">Neuropathy</z:e> Score </plain></SENT>
<SENT sid="5" pm="."><plain><z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">Neuropathy</z:e>-specific QoL was assessed using a DN-specific QoL questionnaire (<z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">Neuropathy</z:e>-Specific Quality of Life Questionnaire [NeuroQoL]) </plain></SENT>
<SENT sid="6" pm="."><plain>Glycosylated <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> and BMI were recorded in <z:hpo ids='HP_0000001'>all</z:hpo> patients.RESULTSNeuroQoL scores indicated significant QoL impairment (mean 9.08 ± 5.93) </plain></SENT>
<SENT sid="7" pm="."><plain>Strength-duration time constant (SDTC), an excitability parameter reflecting <z:chebi fb="199" ids="26708">sodium</z:chebi> channel function, was strongly correlated with QoL scores (r = 0.545; P &lt; 0.005) </plain></SENT>
<SENT sid="8" pm="."><plain>SDTC was prolonged in 48.6% of patients who experienced neuropathic symptoms </plain></SENT>
<SENT sid="9" pm="."><plain>A significant correlation was also noted between SDTC and <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e> severity (r = 0.29; P &lt; 0.05) </plain></SENT>
<SENT sid="10" pm="."><plain>This relationship was strengthened when looking specifically at patients with clinically graded <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e> (r = 0.366; P &lt; 0.05).CONCLUSIONSThe current study has demonstrated an association between markers of <z:chebi fb="199" ids="26708">sodium</z:chebi> channel function and QoL in DN </plain></SENT>
<SENT sid="11" pm="."><plain>The study demonstrates that excitability techniques may identify patients in whom altered <z:chebi fb="199" ids="26708">sodium</z:chebi>-channel function may be the dominant abnormality </plain></SENT>
<SENT sid="12" pm="."><plain>The findings suggest that excitability techniques may have a role in clinical decision making regarding neuropathic treatment prescription </plain></SENT>
</text></document>